Archive for January 8th, 2010

Jet Lag — the Target of the Latest Lifestyle Drug

Friday, January 8th, 2010 by

If you could take a pill to manage your jet lag, would you?  Would it be worth the possibility of dealing with headaches, nausea, dizziness or insomnia as side effects?   Would you be willing to pay more than $9 per dose for this remedy?

Healthy travel takes more than packing a first aid kit and getting the destination-specific vaccinations that you need.  It also includes putting into practice some preventative measures that will keep the journey from wearing down your body and immune system.  This is particularly important if you are traveling overseas, as jet lag can leave your mind fighting to catch up with your body’s cycle the whole duration of your trip.

Now, pharmaceutical company, Cephalon, Frazer, PA, has submitted a jet lag solution to the Food and Drug Administration (FDA) for approval.  The drug is an existing product, Nuvigil, which is used to treat serious sleep disorders and requires a prescription.  According to a news release from Cephalon, this drug offers “improved wakefulness in patients with excessive sleepiness associated with jet lag disorder due to eastbound travel.”   The New York Times reports that clinical trials did show improved levels of wakefulness for those given Nuvigil and that Cephalon is only seeking approval for this as a solution for eastbound travelers because the adjustment for westbound travelers is generally easier.  

Those travelers who only occasionally take an overseas flight might fight the effects of jet lag by following the common practices of upping their post-flight caffeine intake and taking melatonin supplements.  Business travelers and others who frequently travel overseas, however, might see Nuvigil as a valuable traveling companion.  The FDA is expected to complete its review by March 29, 2010; stay tuned for updates.

Photo by Heart Industry http://www.flickr.com/photos/heartindustry/ / CC BY-NC 2.0

Share

H1N1 Update: 2010 Baseline Data Are Encouraging

Friday, January 8th, 2010 by

The flu season in the northern hemisphere has reached its midpoint, and the latest news suggests that the H1N1 outbreak has peaked in most if not all countries. Among the 208 countries where H1N1 has appeared, peak intensity persists in Poland, Serbia, Georgia and Ukraine. H1N1 vaccine is now widely available in the U.S., and many countries in western Europe are cancelling orders for additional vaccine because a single dose has been found to be effective. It’s likely there are continuing vaccine shortages in many developing countries, so travelers to these destinations should not expect to have access to the vaccine while abroad. It’s no surprise that manufacturing and distributing vaccine on a global scale at “break-neck speed” has produced widespread delays and surpluses and shortages.

If you haven’t had a shot, it’s still worth considering (especially if you are under age 30) as world health authorities warn that another wave of H1N1 remains a possibility. Plus, immunizing today is likely to give you some level of protection against related strains in years to come. Of course, everyone always needs to weigh the risks of side effects. Our species may weather this season’s attack without enormous social disruption and loss of life, but we’ve certainly been reminded that luck often outweighs all our furious efforts to protect ourselves.

Share

Organ Transplants: What Are the Risks of Going Abroad?

Friday, January 8th, 2010 by

The recent discovery of a rare amoebic infection in two organ transplant recipients catapulted an unusual, but catastrophic, risk of organ transplantation into international headlines. The Centers for Disease Control reported that four people in three states received organs from a patient suffering from neurological problems who died at the University of Mississippi Medical Center in November.  Two of the organ recipients are now critically ill.      

Transplant patients are particularly susceptible to developing severe symptoms of infectious diseases, as they must be given drugs that weaken the immune system in order to prevent organ rejection.  Although organ donors are routinely tested for common pathogens such as the hepatitis and human immunodeficiency viruses, unusual infectious agents may escape the screening process.  According to Dr. Kenneth Kokko, the medical director of kidney transplants at the University of Mississippi Medical Center, “We test for the known harmful diseases, but there’s not a test for every single pathogen out there.”

Though the occurrence of Balamuthia mandrillaris amoeba is extremely rare, even more common entities, such as bacterial infections, tuberculosis, rabies, and cancer may evade detection prior to the harvesting of organs. Many organ donors are young, healthy victims of severe trauma who have had little or no medical screening.  Such patients may be asymptomatic carriers of chronic infections or have undiagnosed tumors. For example, an Oregon donor in his 40s with a history of alcohol abuse who tested negative for hepatitis C, was later found to have the virus.  Ninety one different tissues and organs were given to forty patients over a 22 month period.  Eight patients were infected, and two later died.  In this case, the donor escaped detection because of the eight to ten week window between infection and the development of detectable blood markers for the disease.

All these cases have been reported in the country with the reputation for the highest standards in medical care. Of course, the potential transmission of life threatening illness is potentially even greater for those wishing to travel overseas for an organ transplant.  Although there are very few U.S. residents who do this today, the number is likely to grow as the availability of organ donors fails to keep pace with the demand.  Indeed, over 9,000 people per year in the U.S. die waiting for organ transplants.  Given the choice between succumbing and finding a donor overseas, most people would be willing to take the risk of an exotic, undetected illness to receive a life saving transplant. Even in the United States, transplant centers seem to be more accepting of deceased donors with high risk behaviors, such as intravenous drug use.  The short interval required to match sick patients with donors also increases the risk of missing a transmissible disease that is not routinely tested for.

In conclusion, “caveat emptor” or “let the buyer beware”  As the widow of one unfortunate recipient commented  “The kidney transplant was supposed to be the gift of life, but the infection that came with it ended up taking it away.”

Share